Cargando…

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

AIMS/HYPOTHESIS: This study aimed to investigate the acute renal effects of the glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide in type 2 diabetes patients. METHODS: We included overweight (BMI 25–40 kg/m(2)) men and postmenopausal women, aged 35–75 years with type 2 diabetes (HbA(1c) 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tonneijck, Lennart, Smits, Mark M., Muskiet, Marcel H. A., Hoekstra, Trynke, Kramer, Mark H. H., Danser, A. H. Jan, Diamant, Michaela, Joles, Jaap A., van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901099/ https://www.ncbi.nlm.nih.gov/pubmed/27038451 http://dx.doi.org/10.1007/s00125-016-3938-z

Ejemplares similares

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
por: Smits, Mark M, et al.
Publicado: (2015)

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients
por: Smits, Mark M., et al.
Publicado: (2016)

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
por: Smits, Mark M., et al.
Publicado: (2016)

Plasma uric acid and renal haemodynamics in type 2 diabetes patients
por: Suijk, Danii LS, et al.
Publicado: (2019)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Renal sinus fat and renal hemodynamics: a cross-sectional analysis
por: Spit, Karlinde A., et al.
Publicado: (2019)

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial
por: Kraaijenhof, Jordan, et al.
Publicado: (2020)

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study
por: Bouman, Emma J., et al.
Publicado: (2021)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
por: Bułdak, Łukasz, et al.
Publicado: (2015)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
por: Chen, Weena J. Y., et al.
Publicado: (2017)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
por: Rosenstock, Julio, et al.
Publicado: (2013)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans
por: van Raalte, Daniël H., et al.
Publicado: (2011)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Proteomic Analysis of INS-1 Rat Insulinoma Cells: ER Stress Effects and the Protective Role of Exenatide, a GLP-1 Receptor Agonist
por: Kim, Mi-Kyung, et al.
Publicado: (2015)

Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress
por: Nomura, Satoshi, et al.
Publicado: (2023)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice
por: Hsu, Brend Ray-Sea, et al.
Publicado: (2016)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models
por: Demkes, Evelyne J., et al.
Publicado: (2021)

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
por: Best, Jennie H., et al.
Publicado: (2011)

The effect of the GLP‐1 analogue Exenatide on functional connectivity within an NTS‐based network in women with and without obesity
por: Coveleskie, K., et al.
Publicado: (2017)

Differential Protective Effects of Exenatide, an Agonist of GLP-1 Receptor and Piragliatin, a Glucokinase Activator in Beta Cell Response to Streptozotocin-Induced and Endoplasmic Reticulum Stresses
por: Kim, Mi-Kyung, et al.
Publicado: (2013)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5dng6apq9skhu0ieqf7hnqs65k